Carey Marrello
Primary Care · Camden, NYNPI 1275150898
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,074 and has fallen 90.5% since, to $102 in 2025.
Across 133 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$343
- Novo Nordisk$286
- Lilly USA, LLC$219
- GSK$203
- Amarin Pharma, Inc.$146
- AstraZeneca$122
- plus $703 from 13 others
What the payments were for
- Food & beverage$2,022100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $343 |
| Novo Nordisk | 20 | $286 |
| Lilly USA, LLC | 17 | $219 |
| GSK | 12 | $203 |
| Amarin Pharma, Inc. | 10 | $146 |
| AstraZeneca | 8 | $122 |
| Amgen(2 entities) | 7 | $114 |
| Biohaven Pharmaceuticals, Inc. | 8 | $113 |
| Boehringer Ingelheim | 6 | $107 |
| Grifols USA, LLC | 6 | $103 |
| Pfizer | 7 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Exact Sciences | 1 | $17 |
| Smith+Nephew | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$2,022 in reported general payments places this provider in the 80th percentile of 239 primary care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 46 | $49,189 |
| JanuviaSitagliptin Phosphate | 33 | $45,788 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $44,947 |
| OzempicSemaglutide | 41 | $41,591 |
| EliquisApixaban | 40 | $39,569 |
| JardianceEmpagliflozin | 15 | $22,601 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $21,467 |
| RybelsusSemaglutide | 19 | $20,755 |
| MyrbetriqMirabegron | 23 | $11,652 |
| VascepaIcosapent Ethyl | 28 | $10,832 |
| XareltoRivaroxaban | 19 | $10,555 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $8,756 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $6,950 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $4,871 |
| Levothyroxine Sodium | 214 | $3,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $286 | $62,34660 claims |
| Lilly USA, LLCMounjaro | $219 | $49,18946 claims |
| MerckJanuvia | $11 | $45,78833 claims |
| GSKTrelegy Ellipta | $203 | $44,94757 claims |
| PfizerEliquis | $99 | $39,56940 claims |
| Boehringer IngelheimJardiance | $107 | $22,60115 claims |
| AstraZenecaBreztri Aerosphere | $122 | $21,46726 claims |
| AbbVieSynthroid | $343 | $1,73439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 239 primary care providers in New York.
Other primary care in Camden
- Dorothy KleinertNew York$27K
- Stephanie KhanForest Hills$16K
- Albert MarcanoJackson Heights$15K
- Elizabeth GattmanJamestown$10K
- Vanessa WangFlushing$10K
- Elizabeth SmithWaterloo$9K
- Eric RodriguezSyracuse$7K
- Natalie Sommerville-BrooksBrooklyn$6K
- Lisa PlanetaNew York$6K
- Pao-Ju TsengFlushing$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.